The story of Sildenafil offers a complicated case study for stakeholders eyeing pharma. While initial sales were remarkable, present patent lapse and the arrival of generic versions have considerably impacted revenues. https://keithsxid547267.blogofchange.com/41677663/the-blue-pill-and-the-pharmaceutical-industry-a-precarious-bet